| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Hannah A Blair | |
| P2860 | cites work | First-in-man study of CPX-351: a liposomal carrier containing cytarabine and daunorubicin in a fixed 5:1 molar ratio for the treatment of relapsed and refractory acute myeloid leukemia. | Q35905061 |
| Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. | Q36219674 | ||
| CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation. | Q39066412 | ||
| In vivo maintenance of synergistic cytarabine:daunorubicin ratios greatly enhances therapeutic efficacy. | Q39954638 | ||
| Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic administration regulates therapeutic activity in tumor-bearing mice | Q40246743 | ||
| Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML. | Q41240646 | ||
| Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study | Q41454879 | ||
| Biophysical characterization of a liposomal formulation of cytarabine and daunorubicin | Q43161582 | ||
| Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts. | Q43170366 | ||
| Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment | Q46931396 | ||
| Improving combination cancer therapy: the CombiPlex® development platform | Q47715078 | ||
| Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach | Q48305735 | ||
| The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. | Q54629037 | ||
| Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML. | Q55472969 | ||
| Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells | Q84002623 | ||
| Pharmacokinetics of CPX-351; a nano-scale liposomal fixed molar ratio formulation of cytarabine:daunorubicin, in patients with advanced leukemia | Q84642891 | ||
| Burden of Acute Myeloid Leukemia Among Older, Newly Diagnosed Patients: Retrospective Analysis of Data From the 2010-2012 Medicare Limited Data Set | Q88412258 | ||
| CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid Leukemia | Q90340566 | ||
| Scavenger receptor class BI (SR-BI) mediates uptake of CPX-351 into K562 leukemia cells | Q90973882 | ||
| Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia | Q91023371 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial | Q6936496 |
| P2507 | corrigendum / erratum | Correction to: Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia | Q60302919 |
| P433 | issue | 18 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| daunorubicin/cytarabine | Q62122683 | ||
| antineoplastic combined chemotherapy protocols | Q66764603 | ||
| P304 | page(s) | 1903-1910 | |
| P577 | publication date | 2018-12-01 | |
| P1433 | published in | Drugs | Q3040094 |
| P1476 | title | Daunorubicin/Cytarabine Liposome: A Review in Acute Myeloid Leukaemia | |
| P478 | volume | 78 |
| Q92784865 | Induction therapy in acute myeloid leukemia: Is it time to put aside standard 3 + 7? |
| Q99419129 | Opto-acoustic synergistic irradiation for vaporization of natural melanin-cored nanodroplets at safe energy levels and efficient sono-chemo-photothermal cancer therapy |
| Q91741269 | The Preparation, Determination of a Flexible Complex Liposome Co-Loaded with Cabazitaxel and β-Elemene, and Animal Pharmacodynamics on Paclitaxel-Resistant Lung Adenocarcinoma |
Search more.